Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Scott Johnston

Interventional Pain Medicine Jacksonville, NC Medical Doctor

NPI 1255351110 CMS profile 283906

250 Huff Dr, Jacksonville, NC 28546

Open in the dashboard

General payments

$20,391

850 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Scott Johnston of Jacksonville, NC is reported in the CMS Open Payments database as having received $20,391 across 850 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,025 105
2024 General $3,242 118
2023 General $4,324 159
2022 General $3,632 127
2021 General $3,523 151
2020 General $1,950 98
2019 General $1,696 92

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Scott Johnston
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Scott Johnston were reported at $2,025. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Scott Johnston Interventional Pain Medicine median Middle half National median
2019 $1,696 $684 $216–$2,079 $163
2020 $1,950 $382 $122–$1,109 $114
2021 $3,523 $552 $167–$1,554 $132
2022 $3,632 $605 $187–$1,924 $149
2023 $4,324 $671 $195–$1,915 $160
2024 $3,242 $684 $206–$1,837 $164
2025 $2,025 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $5,625 163 payments
  2. Boston Scientific Corporation $4,136 162 payments
  3. AbbVie, Inc. $1,231 83 payments
  4. SI-BONE, Inc. $1,068 9 payments
  5. Abbott Laboratories $995 71 payments
  6. Medtronic USA, Inc. $749 36 payments
  7. Forte Bio-Pharma LLC $560 16 payments
  8. Stimwave Technologies Incorporated $492 7 payments
  9. Vertos Medical, Inc. $439 17 payments
  10. Collegium Pharmaceutical, Inc. $437 25 payments
  11. Other $4,659 261 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $17,169 828 payments
  2. Travel and Lodging $3,202 21 payments
  3. Education $19 1 payment
Products named General payments · program years 2019–2025
  1. INTELLIS ADAPTIVESTIM $2,622 89 payments
  2. WaveWriter Alpha Prime 16 $1,429 67 payments
  3. VANTA ADAPTIVESTIM $1,282 13 payments
  4. Superion $967 8 payments
  5. IFUSE IMPLANT SYSTEM $829 5 payments
  6. UBRELVY $615 41 payments
  7. QULIPTA $593 41 payments
  8. INCEPTIV $521 27 payments
  9. SCS FreedonSpinal Cord Stimulator $480 6 payments
  10. CFNS StimQ Peripheral Nerve StimulatorSystem $451 4 payments
  11. Other $12,813 649 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

156

Median for Pain Management: 951

Drug cost

$49,116

Median for Pain Management: $26,034

Branded share of claims

34.6%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Botox Onabotulinumtoxina Brand 38 $46,347
Morphine Sulfate Er Morphine Sulfate Brand 16 $648
Morphine Sulfate Generic 16 $515
Pregabalin Generic 14 $431
Hydromorphone Hcl Generic 15 $429
Oxycodone Hcl Generic 24 $347
Gabapentin Generic 20 $302
Methocarbamol Generic 13 $97

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$107,265

Of which drugs: $1,751

Medicare patients

212

Average age 71

Services billed

3,222

113 women, 99 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Diabetes 34%
Ischemic heart disease 27%
COPD 27%
Chronic kidney disease 25%
Depression 25%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 167 2,251 $1,708
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 28 338 $31

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
$121 — —
UBRELVY
$115 — —
LEVORPHANOL TARTRATE
$102 — —
BOTOX
$80 38 —
MOVANTIK
$72 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

850 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record